Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy

Oncolytic viruses, such as vesicular stomatitis virus (VSV), are a promising class of cancer therapeutics. Here the authors report that a mutation in the CSDE1 gene renders cancer cells resistant to VSV replication and oncolysis, but a mutation-derived escape-associated neoantigen could be exploited...

Full description

Bibliographic Details
Main Authors: Timothy Kottke, Jason Tonne, Laura Evgin, Christopher B. Driscoll, Jacob van Vloten, Victoria A. Jennings, Amanda L. Huff, Brady Zell, Jill M. Thompson, Phonphimon Wongthida, Jose Pulido, Matthew R. Schuelke, Adel Samson, Peter Selby, Elizabeth Ilett, Mark McNiven, Lewis R. Roberts, Mitesh J. Borad, Hardev Pandha, Kevin Harrington, Alan Melcher, Richard G. Vile
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-22115-1

Internet

https://doi.org/10.1038/s41467-021-22115-1

Similar Items